Skip to main content

Significant nodule clearance

Real-world visible results

These adult patients were actual patients (not clinical trial patients) treated with DUPIXENT for ≥24 weeks. Scoring was designated by the healthcare professionals. Because these patients were real-world patients, other factors may have influenced treatment results, and individual results may vary. 

PATIENT 1: 62-YEAR-OLD FEMALE PATIENT WITH A 3-POINT IMPROVEMENT IN IGA PN-S

Current PN therapy: DUPIXENT 300 mg Q2W

DRAG TO SEE
RESULTS

PATIENT 2: 79-YEAR-OLD MALE PATIENT WITH A
2-POINT IMPROVEMENT IN IGA PN-S

Current PN therapy: DUPIXENT 300 mg Q2W

DRAG TO SEE
RESULTS

PATIENT 3: 53-YEAR-OLD FEMALE PATIENT WITH A
2-POINT IMPROVEMENT IN IGA PN-S

Current PN therapy: DUPIXENT 300 mg Q2W

DRAG TO SEE
RESULTS

PATIENT 4: 53-YEAR-OLD FEMALE PATIENT WITH A
2-POINT IMPROVEMENT IN IGA PN-S

Current PN therapy: DUPIXENT 300 mg Q2W

DRAG TO SEE
RESULTS
PRIME 18+ YEARS

PROPORTION OF PATIENT
WITH
IGA PN-S
0 OR 1 AT WEEK 24

(secondary endpoint)1-3,a

aBaseline IGA PN-S scores: 3.3 (SD, 0.5) for DUPIXENT, 3.3 (SD, 0.5) for placebo.

  • A nominal difference was observed at Week 4 (9% with DUPIXENT vs 1% with placebo) and at Week 12 (32% with DUPIXENT vs
    12% with placebo)3

Definitive conclusions cannot be made for results earlier than 24 weeks in PRIME. Data were not multiplicity controlled.

PRIME2 18+ YEARS
  • At Week 4, 8% of patients treated with DUPIXENT vs 6% with placebo had nodule clearance. A significantly greater proportion of DUPIXENT patients achieved nodule clearance at Week 12 (26% with DUPIXENT vs 12% with placebo; P=0.019, secondary endpoint) and Week 24 (45% with DUPIXENT vs 16% with placebo; P<0.001, secondary endpoint)1-3

Definitive conclusions cannot be made for results at timepoints other than Week 12 and 24 in PRIME2. Data were not multiplicity controlled.

PRIME 18+ YEARS

DUPIXENT DEMONSTRATED SIGNIFICANT
NODULE CLEARANCE AT WEEK 24

Click and drag
to see results
PRIME 18+ YEARS

DUPIXENT DEMONSTRATED SIGNIFICANT
NODULE CLEARANCE AT WEEK 24

DRAG TO SEE
RESULTS

Illustrative representation of nodule clearance based on clinical trial results. Actual individual results may vary. 


IGA PN-S ranges from 0 (clear, no nodules) to 1 (almost clear, ≤5 nodules), 2 (mild, 6-19 nodules), 3 (moderate, 20-99 nodules), and 4 (severe, ≥100 nodules).

PRIME2
18+ YEARS
  • 38% of patients had 100 or more nodules at baseline, with 45% of all DUPIXENT patients achieving 5 nodules or fewer at Week 24 vs 16% with placebo1,2

bAll study participants had ≥20 nodules upon screening and at Day 1 (inclusion criteria).

DUPIXENT showed consistent efficacy regardless of patients’ atopic
background1,4

Pooled analysis:
PRIME and PRIME2

Nodule improvement regardless
of patients’ history of atopy

Proportion of patients with IGA PN-S
score of 0 or 1 at Week 241,4

Definitive conclusions cannot be made for these results as the data were not
multiplicity controlled and P values were nominal.

In the PRIME trials, patients were stratified by their history of atopy.

PN is a chronic and distinct dermatologic disease
57%
of patients across PRIME and PRIME2 did not have a history of atopy (defined as having a medical history of atopic dermatitis, allergic rhinitis/rhinoconjunctivitis, asthma, or food allergy)1

IGA PN-S, Investigator’s Global Assessment PN-Stage; PN, prurigo nodularis; Q2W, once every 2 weeks; SD, standard deviation.

EXPLORE COMPOSITE ENDPOINT

See the data